China’s biopharma commands $30 billion in oncology licensing deals, triples US output in 2024
Significant reforms in clinical development processes and regulatory reviews in China have led to faster drug approvals,…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.